Dr. Balevic, et al reply

REFERENCES

1. 1.↵
   1. Joob B,
   2. Wiwanitkit V

   . Evidence of protective effect of hydroxychloroquine on COVID-19. J Rheumatol 2020;47:1587.

   OpenUrlFREE Full Text
2. 2.↵
   1. Yao X,
   2. Ye F,
   3. Zhang M,
   4. Cui C,
   5. Huang B,
   6. Niu P,
   7. et al.

   In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 Mar 9 (E-pub ahead of print).
3. 3.↵
   1. Liu J,
   2. Cao R,
   3. Xu M,
   4. Wang X,
   5. Zhang H,
   6. Hu H,
   7. et al.

   Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Arnold SL,
   2. Buckner F

   . Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. Clin Transl Sci 2020 Apr 8 (E-pub ahead of print).
5. 5.↵
   1. Balevic SJ,
   2. Hornik CP,
   3. Green TP,
   4. Clowse ME,
   5. Gonzalez D,
   6. Maharaj AR,
   7. et al.

   Hydroxychloroquine in patients with rheumatic disease complicated by COVID-19: clarifying target exposures and the need for clinical trials. J Rheumatol 2020 May 11 (in press).
6. 6.↵
   1. McChesney EW

   . Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983;75:11–18.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Konig MF,
   2. Kim AH,
   3. Scheetz MH,
   4. Graef ER,
   5. Liew JW,
   6. Simard J

   Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, et al; COVID-19 Global Rheumatology Alliance. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis 2020 May 7 (E-pub ahead of print).